Search clinical trials for: XL820

Total 7 results

Exelixis

Completed

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

Cancer

United States
Exelixis

Completed

Study of XL820 in Adults With Solid Tumors

Cancer

United States
GlaxoSmithKline

Completed

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Carcinoma, Renal Cell

United States
Exelixis

Completed

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Gastrointestinal Neoplasms | Gastrointestinal Stromal Tumors

United States
GlaxoSmithKline

Completed

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Solid Tumours
GlaxoSmithKline

Completed

Study of GSK1363089 in Metastatic Gastric Cancer

Neoplasms, Gastrointestinal Tract

United States
GlaxoSmithKline

Completed

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Neoplasms, Head and Neck

United States

3

Subscribe